Advertisement

Advertisement

CERO Stock Latest News

CERo Therapeutics Expands Convertible Debt Financing Arrangement

Company AnnouncementsCERo Therapeutics Expands Convertible Debt Financing Arrangement

CERo Therapeutics Amends Convertible Note, Expands Private Financing

PremiumCompany Announcements

CERo Therapeutics Amends Convertible Note, Expands Private Financing

1M ago

CERo Therapeutics Raises Funding via Convertible Note Financing

PremiumCompany Announcements

CERo Therapeutics Raises Funding via Convertible Note Financing

2M ago

CERo Therapeutics Raises Capital via Convertible Note Financing

PremiumCompany Announcements

CERo Therapeutics Raises Capital via Convertible Note Financing

3M ago

CERo Therapeutics Secures Convertible Note Financing Facility

PremiumCompany Announcements

CERo Therapeutics Secures Convertible Note Financing Facility

4M ago

CERo Therapeutics Delays 2025 Annual Report Filing

PremiumCompany AnnouncementsCERo Therapeutics Delays 2025 Annual Report Filing

4M ago

Cero Therapeutics issues letter to shareholders

The Fly

Cero Therapeutics issues letter to shareholders

5M ago

CERo Therapeutics Enters Convertible Note Financing Agreement

Company Announcements

CERo Therapeutics Enters Convertible Note Financing Agreement

5M ago

Cero Therapeutics appoints Eric Francois to board of directors

PremiumThe Fly

Cero Therapeutics appoints Eric Francois to board of directors

5M ago

CERo Therapeutics Announces Convertible Note Financing and New Director

PremiumCompany Announcements

CERo Therapeutics Announces Convertible Note Financing and New Director

6M ago

Cero Therapeutics to present data from Phase 2 trial of CER-1236

PremiumThe Fly

Cero Therapeutics to present data from Phase 2 trial of CER-1236

6M ago

CERo Therapeutics Securities Delisted Following Nasdaq Appeal Denial

PremiumCompany Announcements

CERo Therapeutics Securities Delisted Following Nasdaq Appeal Denial

6M ago

CERo Therapeutics reports encouraging early CERTAINT-1 trial data

PremiumCompany AnnouncementsCERo Therapeutics reports encouraging early CERTAINT-1 trial data

7M ago

Cero Therapeutics provides update on Phase 1 trial of CER-1236

The Fly

Cero Therapeutics provides update on Phase 1 trial of CER-1236

7M ago

CERo Therapeutics shareholders approve key capital structure changes

Company Announcements

CERo Therapeutics shareholders approve key capital structure changes

7M ago

Cero Therapeutics provides update on Phase 1 trial of CER-1236

PremiumThe Fly

Cero Therapeutics provides update on Phase 1 trial of CER-1236

8M ago

CERo Therapeutics Enters New $14.6M Stock Agreement

PremiumCompany Announcements

CERo Therapeutics Enters New $14.6M Stock Agreement

8M ago

Cero Therapeutics announces trading on OTCQB Market

PremiumThe Fly

Cero Therapeutics announces trading on OTCQB Market

8M ago

Cero Therapeutics downgraded to Hold from Buy at D. Boral Capital

PremiumThe Fly

Cero Therapeutics downgraded to Hold from Buy at D. Boral Capital

8M ago

CERo Therapeutics Delays Quarterly Report Filing

PremiumCompany AnnouncementsCERo Therapeutics Delays Quarterly Report Filing

9M ago

Cero Therapeutics initiates second cohort in Phase 1 trial of CER-1236

The Fly

Cero Therapeutics initiates second cohort in Phase 1 trial of CER-1236

9M ago

Cero Therapeutics to present data on CER-1236 at SITC conference

The Fly

Cero Therapeutics to present data on CER-1236 at SITC conference

9M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >